Related Experiment Video
Updated: May 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial
Andrew Dauber1, Liat Corcia, Jason Safer
1Division of Endocrinology, Boston Children’s Hospital, Boston, MA, USA.
Diabetes Care
|October 4, 2012
Summary
Closed-loop insulin therapy shows promise for improving overnight glucose control in young children with type 1 diabetes. This advanced system reduces hyperglycemia without increasing hypoglycemia, preparing them better for meals.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disease Research
- Diabetes Technology
Background:
- Type 1 diabetes management in young children presents unique challenges.
- Optimizing glycemic control is crucial for preventing long-term complications.
- Insulin pump therapy is a common treatment modality.
Purpose of the Study:
- To evaluate the efficacy of closed-loop insulin therapy in enhancing nocturnal glycemic control.
- To assess the impact of closed-loop therapy on meal glycemic response in children under 7 years old.
- To compare closed-loop with open-loop insulin pump therapy.
Main Methods:
- Randomized controlled crossover trial conducted in an inpatient setting.
- Ten children under 7 years with type 1 diabetes using insulin pumps participated.
- Comparison of closed-loop vs. standard open-loop therapy over 2 consecutive days, focusing on overnight and postprandial periods.
Main Results:
- Closed-loop therapy demonstrated a significant reduction in time spent with glucose levels >300 mg/dL overnight (P=0.035).
- A trend towards improved time in range (110-200 mg/dL) overnight was observed (P=0.12).
- Closed-loop therapy improved pre-meal glucose levels compared to open-loop (189 vs. 273 mg/dL, P=0.009) without increasing hypoglycemia.
Conclusions:
- Closed-loop insulin delivery effectively reduces overnight hyperglycemia in young children with type 1 diabetes.
- This therapy improves glucose normalization before subsequent meals.
- Young children with type 1 diabetes may benefit significantly from closed-loop systems.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...